Clinical Efiicacy of Marichyadi Lepa and Abhayarishta on Shvitra (Vitiligo)

Development of Pharmaceutico-Analytical profiles of Marichyadi Lepa and Abhayarishta and their efficacy on Shvitra (Vitiligo) - A Randomized, Single blind trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/02/007929

Enrollment

Registered

2017-02-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients having signs and symptoms of Shvitra (Vitiligo).

Interventions

Intervention1: Marichyadi Lepa with Bhanupaka method: For local application in QS dose Control Intervention1: Marichyadi Lepa with Agnipaka method: For local application in QS dose

Eligibility

Inclusion criteria

Inclusion criteria: Patients having signs and symptoms of Shvitra (leucoderma) Patient between the age of 16 to 60 years Patients with chronicity of less than 10 years

Exclusion criteria

Exclusion criteria: Patients with Chronicity more than 10 years Patient below the age of 16 and above the age of 60 years Patients having serious cardiac renal hepatic diseases major illness like IDDM NIDDM patches due to burning chemical explosion any other serious systemic illness Gravid and lactating women Cases with Asadhya Lakshanas of Shvitra

Design outcomes

Primary

Measure	Time frame
It is expected that the trial drugs will exert a significant improvement in combating shvitraTimepoint: The effect will be assessed on the basis of subjective and objective criteria Improvement in the signs and symptoms will be analysed on the basis of special adopted scoring pattern for scrutinizing the symptomatology The score will be given on the basis of site size colour numbers and chronicity of the patches etc	—

Measure

Time frame

It is expected that the trial drugs will exert a significant improvement in combating shvitraTimepoint: The effect will be assessed on the basis of subjective and objective criteria Improvement in the signs and symptoms will be analysed on the basis of special adopted scoring pattern for scrutinizing the symptomatology The score will be given on the basis of site size colour numbers and chronicity of the patches etc

—

Secondary

Measure	Time frame
By providing better effect on Shvitra,the drug will effect psychosomatic level of the enrolled patients, enhance quality of life and will contribute in reducing social stigma of the patients affecting with Shvitra. Overall improvement in the disease condition, Quality of Life of the diseased. Based on the observations, the trial drug may be recommended to be added into the Essential Drugs List of Ministry of AYUSH, New DelhiTimepoint: 18 Months of Trial	—

Measure

Time frame

By providing better effect on Shvitra,the drug will effect psychosomatic level of the enrolled patients, enhance quality of life and will contribute in reducing social stigma of the patients affecting with Shvitra. Overall improvement in the disease condition, Quality of Life of the diseased. Based on the observations, the trial drug may be recommended to be added into the Essential Drugs List of Ministry of AYUSH, New DelhiTimepoint: 18 Months of Trial

—

Countries

India

Contacts

Public ContactDr Galib

IPGT and RA

drprashantbedarkar@gmail.com8128217370

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026